Upstate Active Clinical Trials

Study Title:

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

What is the purpose of the study?

Treatment study to improve cure rate for AML by adding bortezomib, to the standard chemotherapy regimen, to find out the dose and effectiveness of sorafenib & to better understand the biology of AML better.

Upstate Institutional Review Board (IRB) Number:

253382

Study/Protocol ID:

AAML1031

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Karol H Kerr, MD

ClinicalTrials.Gov ID:

NCT01371981

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again